1,22-bis-(methanesulfonyloxy)docosane | 1424372-74-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: 1,22-bis-(methanesulfonyloxy)docosane
• CAS: 1424372-74-6
• 化学式: C₂₄H₅₀O₆S₂
• 分子量: 498.789
• InChiKey: ZMUYKEMTCYDSRA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.74
• 重原子数：
  32.0
• 可旋转键数：
  25.0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  86.74
• 氢给体数：
  0.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  N-甲基咪唑 、 1,22-bis-(methanesulfonyloxy)docosane 以 丙酮 为溶剂， 反应 13.0h， 以85%的产率得到1,22-bis-(3-methyl-1H-imidazolium-1-yl)docosane dimesylate
  参考文献：
  名称：

  Selective inhibition of glycosyltransferases by bivalent imidazolium salts

  摘要：

  Galactosyltransferases (GalTs) extend the glycan chains of mammalian glycoproteins by adding Gal to terminal GlcNAc residues, and thus build the scaffolds for biologically important glycan structures. We have shown that positively charged bivalent imidazolium salts in which the two imidazolium groups are linked by an aliphatic chain of 20 or 22 carbons form potent inhibitors of purified human beta 3-GalT5, using GlcNAc beta-benzyl as acceptor substrate. The inhibitors are not substrate analogs and also inhibited a selected number of other glycosyltransferases. These bis-imidazolium compounds represent a new class of glycosyltransferase inhibitors with potential as anti-cancer and anti-inflammatory drugs. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.12.034
• 作为产物：
  描述：

  L,22-二十二碳二醇 、 甲基磺酰氯 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 19.0h， 以81%的产率得到1,22-bis-(methanesulfonyloxy)docosane
  参考文献：
  名称：

  Selective inhibition of glycosyltransferases by bivalent imidazolium salts

  摘要：

  Galactosyltransferases (GalTs) extend the glycan chains of mammalian glycoproteins by adding Gal to terminal GlcNAc residues, and thus build the scaffolds for biologically important glycan structures. We have shown that positively charged bivalent imidazolium salts in which the two imidazolium groups are linked by an aliphatic chain of 20 or 22 carbons form potent inhibitors of purified human beta 3-GalT5, using GlcNAc beta-benzyl as acceptor substrate. The inhibitors are not substrate analogs and also inhibited a selected number of other glycosyltransferases. These bis-imidazolium compounds represent a new class of glycosyltransferase inhibitors with potential as anti-cancer and anti-inflammatory drugs. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.12.034